中文摘要：

[目的]评价非小细胞肺癌（NSCI．C）患者血清糖类抗原（CA125）水平与疾病进展时间（TFP）的关系。[方法]对中国中医科学院广安门医院2006年10月-2009年10月收治的154例非小细胞肺癌患者的血清CA125水平与疾病进展时间的相关性进行回顾性研究。[结果]血清CA125水平与临床分期相关，Ⅳ期患者血清CA125水平明显高于ⅢB期（P〈0．05）。血清CA125水平≥123U／ml的患者半年内进展的风险比CA125水平〈123U／ml的患者增加89％（OR=1．889，95％CI：1．254-2．845，P=0．002）。[结论]血清CA125水平与患者疾病进展时间有明硅的相关性．町通过检测CA125水平判断患者预后。

英文摘要：

Abstract： [PurposelTo analyze the correlation between serum CA125 and time to progression （TTP） in the patients with non-small cell lung cancer （NSCLC）. [Methodsl Retrospective study on the correlation between serum CA125 and TFP was conducted in 154 NSCLC cases from Guang＇ anmen Hospital, China Academy of Chinese Medical Science. [Resultsl The level of serum CA125in patients with stage Ⅳ was significantly higher than that in those with stage Ⅲ B （P〈0.05）. In term of tumour progress risk in 6 months, the patients with a high level of serum CA125 （3 123U/ ml） had 89% higher risk than patients with a low level of serum CA125 （〈123U/ml） （P=0.002）. [Couclusionl There is obvious correlation between the serum level of CA125 and TFP in patients with NSCI,C. The serum level of CA125 is a helpful prognostic index, which is especially valuable to evaluate prognosis and to establish the clinical therapeutic prnject.